Healthcare

Vitiligo Treatment Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Vitiligo Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Vitiligo Treatment Market:

https://www.thebusinessresearchcompany.com/report/vitiligo-treatment-global-market-report

According to The Business Research Company’s Vitiligo Treatment Global Market Report 2024, The vitiligo treatment market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased prevalence of vitiligo, advancements in dermatology research, improving patient awareness, diverse treatment modalities, patient-centric approach in healthcare..

The vitiligo treatment market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to innovations in immunomodulatory therapies, increasing research funding, global health initiatives for dermatological conditions, growing acceptance of combination therapies, enhanced dermatology care infrastructure.. Major trends in the forecast period include combination therapies, research and development, patient-centric approaches, global awareness and advocacy, regulatory landscape..

The rise in healthcare expenditure is expected to propel the growth of the vitiligo treatment market going forward. Healthcare expenditure refers to an expense that covers all costs associated with providing health services, family planning, nutrition, and emergency help with a focus on health. Improved healthcare expenditure will aid in providing better treatment to all patients suffering from vitiligo. Additionally, effective primary healthcare will promote population health through the integration of primary care services with public health. For instance, in March 2022, according to the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021–2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, the rise in healthcare expenditure is driving the growth of the vitiligo treatment market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10843&type=smp

The vitiligo treatment market covered in this report is segmented –

1) By Drugs: Antihistamines, H2 Antagonists, Tricyclic Antidepressants, Other Drugs

2) By Types: Acute Urticaria, Chronic Urticaria

3) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Product innovations are a key trend gaining popularity in the vitiligo treatment market. Companies operating in the vitiligo treatment market are focused on introducing new products to sustain their position in the market. For instance, in July 2022, Incyte Corporation, a US-based pharmaceutical firm, announced that the FDA has authorized OpzeluraTM (ruxolitinib) cream 1.5% for the topical treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is licensed for continued topical application twice daily to afflicted regions of up to 10% of the body surface area in individuals with non-segmental vitiligo. Patients who received Opzelura at Week 24 showed a consistent 75% improvement from baseline in the face Vitiligo Area Scoring Index (F-VASI75).

The vitiligo treatment market report table of contents includes: